Johannes Roth1, Oliver Sommerfeld, Andreas L Birkenfeld, Christoph Sponholz, Ulrich A Müller, Christian von Loeffelholz. 1. Dept. for Anesthesiology and Intensive Care Medicine, University Hospital of the Friedrich-Schiller University Jena, Jena, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany; King´s College London, Department of Diabetes, School of Life Course Science, London, UK; Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the University of Tübingen, Germany; Division IV (Diabetology, Endocrinology, Nephrology) of the Department of Internal Medicine at the University Hospital Tübingen, Germany; Practice for Diabetology and Endocrinology, Dr. Kielstein, Outpatient Healthcare Center Erfurt, Jena.
Abstract
BACKGROUND: 30-80% of patients being treated in intensive care units in the perioperative period develop hyperglycemia. This stress hyperglycemia is induced and maintained by inflammatory-endocrine and iatrogenic stimuli and generally requires treatment. There is uncertainty regarding the optimal blood glucose targets for patients with diabetes mellitus. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed and Google Scholar. RESULTS: Patients in intensive care with pre-existing diabetes do not benefit from blood sugar reduction to the same extent as metabolically healthy individuals, but they, too, are exposed to a clinically relevant risk of hypoglycemia. A therapeutic range from 4.4 to 6.1 mmol/L (79-110 mg/dL) cannot be justified for patients with diabetes mellitus. The primary therapeutic strategy in the perioperative setting should be to strictly avoid hypoglycemia. Neurotoxic effects and the promotion of wound-healing disturbances are among the adverse consequences of hyperglycemia. Meta-analyses have shown that an upper blood sugar limit of 10 mmol/L (180 mg/dL) is associated with better outcomes for diabetic patients than an upper limit of less than this value. The target range of 7.8-10 mmol/L (140-180 mg/dL) proposed by specialty societies for hospitalized patients with diabetes seems to be the best compromise at present for optimizing clinical outcomes while avoiding hypoglycemia. The method of choice for achieving this goal in intensive care medicine is the continuous intravenous administration of insulin, requirng standardized, high-quality monitoring conditions. CONCLUSION: Optimal blood sugar control for diabetic patients in intensive care meets the dual objectives of avoiding hypoglycemia while keeping the blood glucose concentration under 10 mmol/L (180 mg/dL). Nutrition therapy in accordance with the relevant guidelines is an indispensable pre - requisite.
BACKGROUND: 30-80% of patients being treated in intensive care units in the perioperative period develop hyperglycemia. This stress hyperglycemia is induced and maintained by inflammatory-endocrine and iatrogenic stimuli and generally requires treatment. There is uncertainty regarding the optimal blood glucose targets for patients with diabetes mellitus. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed and Google Scholar. RESULTS: Patients in intensive care with pre-existing diabetes do not benefit from blood sugar reduction to the same extent as metabolically healthy individuals, but they, too, are exposed to a clinically relevant risk of hypoglycemia. A therapeutic range from 4.4 to 6.1 mmol/L (79-110 mg/dL) cannot be justified for patients with diabetes mellitus. The primary therapeutic strategy in the perioperative setting should be to strictly avoid hypoglycemia. Neurotoxic effects and the promotion of wound-healing disturbances are among the adverse consequences of hyperglycemia. Meta-analyses have shown that an upper blood sugar limit of 10 mmol/L (180 mg/dL) is associated with better outcomes for diabetic patients than an upper limit of less than this value. The target range of 7.8-10 mmol/L (140-180 mg/dL) proposed by specialty societies for hospitalized patients with diabetes seems to be the best compromise at present for optimizing clinical outcomes while avoiding hypoglycemia. The method of choice for achieving this goal in intensive care medicine is the continuous intravenous administration of insulin, requirng standardized, high-quality monitoring conditions. CONCLUSION: Optimal blood sugar control for diabetic patients in intensive care meets the dual objectives of avoiding hypoglycemia while keeping the blood glucose concentration under 10 mmol/L (180 mg/dL). Nutrition therapy in accordance with the relevant guidelines is an indispensable pre - requisite.
Authors: Simon Finfer; Dean R Chittock; Steve Yu-Shuo Su; Deborah Blair; Denise Foster; Vinay Dhingra; Rinaldo Bellomo; Deborah Cook; Peter Dodek; William R Henderson; Paul C Hébert; Stephane Heritier; Daren K Heyland; Colin McArthur; Ellen McDonald; Imogen Mitchell; John A Myburgh; Robyn Norton; Julie Potter; Bruce G Robinson; Juan J Ronco Journal: N Engl J Med Date: 2009-03-24 Impact factor: 91.245
Authors: Tien F Lee; Sophie M Drake; Gregory W Roberts; Andrew Bersten; Stephen N Stranks; Leonie K Heilbronn; Arduino A Mangoni; Morton G Burt Journal: Crit Care Med Date: 2020-02 Impact factor: 7.598
Authors: Guillermo E Umpierrez; Richard Hellman; Mary T Korytkowski; Mikhail Kosiborod; Gregory A Maynard; Victor M Montori; Jane J Seley; Greet Van den Berghe Journal: J Clin Endocrinol Metab Date: 2012-01 Impact factor: 5.958
Authors: Gunjan Y Gandhi; Gregory A Nuttall; Martin D Abel; Charles J Mullany; Hartzell V Schaff; Peter C O'Brien; Matthew G Johnson; Arthur R Williams; Susanne M Cutshall; Lisa M Mundy; Robert A Rizza; M Molly McMahon Journal: Ann Intern Med Date: 2007-02-20 Impact factor: 25.391
Authors: Pierre Singer; Annika Reintam Blaser; Mette M Berger; Waleed Alhazzani; Philip C Calder; Michael P Casaer; Michael Hiesmayr; Konstantin Mayer; Juan Carlos Montejo; Claude Pichard; Jean-Charles Preiser; Arthur R H van Zanten; Simon Oczkowski; Wojciech Szczeklik; Stephan C Bischoff Journal: Clin Nutr Date: 2018-09-29 Impact factor: 7.324
Authors: James S Krinsley; Marcus J Schultz; Peter E Spronk; Robin E Harmsen; Floris van Braam Houckgeest; Johannes P van der Sluijs; Christian Mélot; Jean Charles Preiser Journal: Crit Care Date: 2011-07-25 Impact factor: 9.097
Authors: Guillermo Umpierrez; Saumeth Cardona; Francisco Pasquel; Sol Jacobs; Limin Peng; Michael Unigwe; Christopher A Newton; Dawn Smiley-Byrd; Priyathama Vellanki; Michael Halkos; John D Puskas; Robert A Guyton; Vinod H Thourani Journal: Diabetes Care Date: 2015-07-15 Impact factor: 19.112